Pulmonary Function Testing (PFT) is a crucial tool in diagnosing and managing respiratory diseases. However, its interpretation can be complex due to the numerous variables involved. This article aims to provide a comprehensive guide to aid healthcare professionals in decoding PFT results.
The primary components of PFT include spirometry, lung volumes, and diffusion capacity. Spirometry measures the volume and speed of air that can be inhaled and exhaled, while lung volumes assess the total capacity of the lungs. Diffusion capacity evaluates how well the lungs exchange gases.
Spirometry results are interpreted using Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1). A reduced FEV1/FVC ratio indicates obstructive disease, while a normal ratio with decreased volumes suggests restrictive pathology.
Increased residual volume (RV) and total lung capacity (TLC) are indicative of obstructive diseases. In contrast, reduced TLC points towards a restrictive pattern. The measurement of functional residual capacity (FRC) can also provide insight into air trapping and hyperinflation.
Diffusion capacity of the lung for carbon monoxide (DLCO) is a sensitive marker for alveolar-capillary membrane integrity. A reduced DLCO suggests emphysema or interstitial lung disease, while increased DLCO can be seen in conditions like polycythemia or left-to-right cardiac shunts.
Interpreting PFT requires a thorough understanding of its components and their implications. By correctly deciphering these results, healthcare professionals can provide accurate diagnoses and effective treatment plans for their patients. Continuous education and practice are key to mastering the interpretation of this valuable diagnostic tool.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation